Clinical efficacy of anakinra to mitigate CAR T-cell therapy associated toxicity in large B-cell lymphoma

Paolo Strati; Sairah Ahmed; Partow Kebriaei; Loretta J. Nastoupil; Catherine M. Claussen; Grace Watson; Sandra B. Horowitz; Anne Rain T. Brown; Bryan Do; Maria A. Rodriguez; Ranjit Nair; Elizabeth J. Shpall; Michael R. Green; Sattva S. Neelapu; Jason R. Westin

doi:10.1182/bloodadvances.2020002328

Clinical efficacy of anakinra to mitigate CAR T-cell therapy associated toxicity in large B-cell lymphoma

Paolo Strati, Sairah Ahmed, Partow Kebriaei, Loretta J. Nastoupil, Catherine M. Claussen, Grace Watson, Sandra B. Horowitz, Anne Rain T. Brown, Bryan Do, Maria A. Rodriguez, Ranjit Nair, Elizabeth J. Shpall, Michael R. Green, Sattva S. Neelapu, Jason R. Westin

Lymphoma-Myeloma

Research output: Contribution to journal › Letter › peer-review

136 Scopus citations

Original language	English (US)
Pages (from-to)	3123-3127
Number of pages	5
Journal	Blood Advances
Volume	4
Issue number	13
DOIs	https://doi.org/10.1182/bloodadvances.2020002328
State	Published - Jul 14 2020

ASJC Scopus subject areas

Hematology

Access to Document

10.1182/bloodadvances.2020002328

Cite this

Strati, P., Ahmed, S., Kebriaei, P., Nastoupil, L. J., Claussen, C. M., Watson, G., Horowitz, S. B., Brown, A. R. T., Do, B., Rodriguez, M. A., Nair, R., Shpall, E. J., Green, M. R., Neelapu, S. S., & Westin, J. R. (2020). Clinical efficacy of anakinra to mitigate CAR T-cell therapy associated toxicity in large B-cell lymphoma. Blood Advances, 4(13), 3123-3127. https://doi.org/10.1182/bloodadvances.2020002328

Strati, P , Ahmed, S , Kebriaei, P, Nastoupil, LJ, Claussen, CM, Watson, G, Horowitz, SB, Brown, ART, Do, B, Rodriguez, MA, Nair, R , Shpall, EJ , Green, MR , Neelapu, SS & Westin, JR 2020, 'Clinical efficacy of anakinra to mitigate CAR T-cell therapy associated toxicity in large B-cell lymphoma', Blood Advances, vol. 4, no. 13, pp. 3123-3127. https://doi.org/10.1182/bloodadvances.2020002328

@article{ac571269b2d74c769a9ef5c018d82901,

title = "Clinical efficacy of anakinra to mitigate CAR T-cell therapy associated toxicity in large B-cell lymphoma",

author = "Paolo Strati and Sairah Ahmed and Partow Kebriaei and Nastoupil, {Loretta J.} and Claussen, {Catherine M.} and Grace Watson and Horowitz, {Sandra B.} and Brown, {Anne Rain T.} and Bryan Do and Rodriguez, {Maria A.} and Ranjit Nair and Shpall, {Elizabeth J.} and Green, {Michael R.} and Neelapu, {Sattva S.} and Westin, {Jason R.}",

note = "Funding Information: Conflict-of-interest disclosure: S.S.N. has received honoraria and research support from Kite, a Gilead company, Merck, and Celgene; research support from Bristol-Myers Squibb, Poseida, Cellectis, Karus, and Acerta Pharma; and honoraria from Novartis, Pfizer, and Unum Therapeutics. L.J.N. has received honoraria from Celgene, Genentech, Gilead, Janssen, Juno, Novartis, and Spectrum; and research support from Celgene, Genentech, Janssen, and Merck. J.R.W. has received honoraria and research support from Kite, Bristol-Myers Squibb, Novartis, and Unum Therapeutics. The remaining authors declare no competing financial interests. Funding Information: Acknowledgments: This work was supported by National Institutes of Health, National Cancer Institute grant P30 CA016672 (MD Anderson Cancer Center). P.S. is supported by a Lymphoma Research Foundation Career Development Award, and M.R.G. by a Leukemia and Lymphoma Society Scholar Award.",

year = "2020",

month = jul,

day = "14",

doi = "10.1182/bloodadvances.2020002328",

language = "English (US)",

volume = "4",

pages = "3123--3127",

journal = "Blood Advances",

issn = "2473-9529",

publisher = "American Society of Hematology",

number = "13",

}

TY - JOUR

T1 - Clinical efficacy of anakinra to mitigate CAR T-cell therapy associated toxicity in large B-cell lymphoma

AU - Strati, Paolo

AU - Ahmed, Sairah

AU - Kebriaei, Partow

AU - Nastoupil, Loretta J.

AU - Claussen, Catherine M.

AU - Watson, Grace

AU - Horowitz, Sandra B.

AU - Brown, Anne Rain T.

AU - Do, Bryan

AU - Rodriguez, Maria A.

AU - Nair, Ranjit

AU - Shpall, Elizabeth J.

AU - Green, Michael R.

AU - Neelapu, Sattva S.

AU - Westin, Jason R.

N1 - Funding Information: Conflict-of-interest disclosure: S.S.N. has received honoraria and research support from Kite, a Gilead company, Merck, and Celgene; research support from Bristol-Myers Squibb, Poseida, Cellectis, Karus, and Acerta Pharma; and honoraria from Novartis, Pfizer, and Unum Therapeutics. L.J.N. has received honoraria from Celgene, Genentech, Gilead, Janssen, Juno, Novartis, and Spectrum; and research support from Celgene, Genentech, Janssen, and Merck. J.R.W. has received honoraria and research support from Kite, Bristol-Myers Squibb, Novartis, and Unum Therapeutics. The remaining authors declare no competing financial interests. Funding Information: Acknowledgments: This work was supported by National Institutes of Health, National Cancer Institute grant P30 CA016672 (MD Anderson Cancer Center). P.S. is supported by a Lymphoma Research Foundation Career Development Award, and M.R.G. by a Leukemia and Lymphoma Society Scholar Award.

PY - 2020/7/14

Y1 - 2020/7/14

UR - http://www.scopus.com/inward/record.url?scp=85090350518&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85090350518&partnerID=8YFLogxK

U2 - 10.1182/bloodadvances.2020002328

DO - 10.1182/bloodadvances.2020002328

M3 - Letter

C2 - 32645136

AN - SCOPUS:85090350518

SN - 2473-9529

VL - 4

SP - 3123

EP - 3127

JO - Blood Advances

JF - Blood Advances

IS - 13

ER -

Clinical efficacy of anakinra to mitigate CAR T-cell therapy associated toxicity in large B-cell lymphoma

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this